Coloplast Publishes Q4 2026 Earnings Call Transcript
Bitget2026/11/04 10:06- Coloplast’s Nov. 3, 2026, fourth-quarter earnings call featured CEO Gavin Wood and CFO Anders Lonning-Skovgaard, with analysts participating.
- Management revised ambitions through fiscal 2029/30 to annual organic growth of 5%-7% and an EBIT margin in the mid-20s at constant currencies.
- The revision reflects healthcare pricing pressure, US outpatient Biologics reimbursement changes and increased investment in innovation and US growth.
- Fiscal 2026/27 guidance targets organic revenue growth of 5%-7% and an EBIT margin around 25%, with improvement expected from the second quarter.
- The resource-reallocation program targets DKK 500 million, with approximately 80% earmarked for stepped-up investments and full benefits expected in fiscal 2027/28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
